# Psilocybin, Cortical Plasticity and Durable Antidepressant Response: research update

Dated 5 October 2026. Local prepublication addendum; archived grade unchanged.

Clinical trials support symptom effects in selected settings, and mouse experiments establish specific receptor/cell dependencies. These findings do not yet show that a temporary rise in human structural plasticity mediates lasting antidepressant benefit; recent null and context-dependent results are central to that distinction.

## Research timeline

Electronic year is used where recorded; issue year is retained in each source card. The chronology is selected, not exhaustive, and does not establish priority or causation.

| Year | Primary study | Design and finding | Inference limit |
|---|---|---|---|
| 2016 | [Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.](https://pubmed.ncbi.nlm.nih.gov/27210031/) | Open-label depression feasibility study. Symptoms improved after psilocybin with psychological support. | Small uncontrolled study cannot separate drug, expectancy, support and natural course. |
| 2021 | [Trial of Psilocybin versus Escitalopram for Depression.](https://pubmed.ncbi.nlm.nih.gov/33852780/) | Psilocybin versus escitalopram randomized trial. The primary depression outcome did not show a significant between-treatment difference. | Secondary outcomes favoured psilocybin but lacked multiplicity correction; support accompanied treatment. |
| 2021 | [Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.](https://pubmed.ncbi.nlm.nih.gov/34228959/) | Mouse longitudinal spine imaging. A single dose increased frontal dendritic-spine measures for weeks. | Mouse structural change does not establish mediation of human depression relief. |
| 2022 | [Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.](https://pubmed.ncbi.nlm.nih.gov/36322843/) | Treatment-resistant depression dose trial. The higher dose improved the short-term primary outcome over low dose. | Durability and adverse-event findings bound benefit; low-dose control does not guarantee successful blinding. |
| 2023 | [Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/37651119/) | Psilocybin versus niacin MDD randomized trial. Depressive symptoms and disability improved through the measured follow-up. | Acute experiential differences and psychological support complicate causal component separation. |
| 2025 | [Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.](https://pubmed.ncbi.nlm.nih.gov/40175553/) | Mouse cell-type silencing and receptor deletion. PT-cell activity and targeted 5-HT2A receptors were required for selected lasting effects. | Blocking a receptor/cell affects multiple processes; it does not isolate structural plasticity as the mediator. |
| 2025 | [Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity.](https://pubmed.ncbi.nlm.nih.gov/41224969/) | Rodent long-term functional/structural comparison. Enduring behaviour and functional plasticity occurred without detected structural-density changes. | Species, sampling and measurement sensitivity limit how broadly this structural null applies. |
| 2026 | [Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/42138922/) | Major-depression randomized trial. Rapid symptom benefit was reported; some late effects were secondary outcomes and anxiety required care in some participants. | Endpoint hierarchy and follow-up attrition must remain visible in durability claims. |
| 2026 | [Psilocybin's effect on human brain synaptic plasticity.](https://pubmed.ncbi.nlm.nih.gov/42457666/) | Human SV2A PET before/after dosing. The report found no significant overall synaptic-density increase; setting-related differences were observed. | Small context-dependent before/after study is not a randomized mediator test or universal absence of plasticity. |

## Research gaps

### G1: Does structural plasticity mediate human clinical benefit?

Evidence anchors: [P34228959](https://pubmed.ncbi.nlm.nih.gov/34228959/), [P40175553](https://pubmed.ncbi.nlm.nih.gov/40175553/), [P41224969](https://pubmed.ncbi.nlm.nih.gov/41224969/), [P42457666](https://pubmed.ncbi.nlm.nih.gov/42457666/).

Competing explanation: Functional adaptation or support-related learning may matter without increased synaptic density.

Discriminating test and controls: Randomized clinical studies with time-ordered orthogonal plasticity measures, functional readouts and symptoms; complement with selective mediator perturbation in models.

### G2: Which component is drug action versus expectancy and support?

Evidence anchors: [P27210031](https://pubmed.ncbi.nlm.nih.gov/27210031/), [P33852780](https://pubmed.ncbi.nlm.nih.gov/33852780/), [P37651119](https://pubmed.ncbi.nlm.nih.gov/37651119/).

Competing explanation: Acute subjective effects can reveal allocation and modify learning or clinician interactions.

Discriminating test and controls: Prespecified masking assessment, credible comparators and standardized support; where feasible compare support components while retaining treatment fidelity.

### G3: Which receptor/cell dependency translates to humans?

Evidence anchors: [P40175553](https://pubmed.ncbi.nlm.nih.gov/40175553/), [P42457666](https://pubmed.ncbi.nlm.nih.gov/42457666/), [P34228959](https://pubmed.ncbi.nlm.nih.gov/34228959/).

Competing explanation: A mouse cell-type dependency may reflect acute excitability rather than the proposed human repair mechanism.

Discriminating test and controls: Independent model replication with acute versus delayed interventions and human target-engagement measures; separate receptor necessity from mediator necessity.

### G4: How durable are benefits and who is harmed or fails to respond?

Evidence anchors: [P36322843](https://pubmed.ncbi.nlm.nih.gov/36322843/), [P42138922](https://pubmed.ncbi.nlm.nih.gov/42138922/), [P37651119](https://pubmed.ncbi.nlm.nih.gov/37651119/), [P33852780](https://pubmed.ncbi.nlm.nih.gov/33852780/).

Competing explanation: Selected samples, retreatment, added care or dropout can shape follow-up effects.

Discriminating test and controls: Longer blinded follow-up with predefined relapse, retreatment, co-interventions and adverse-event ascertainment; prespecified subgroup interactions.

## Methods and access

Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.

This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.

Checked timeline sources: 9; selected full-text checks: 1; abstract-excerpt checks: 8; metadata-only historical anchors: 0. Complete papers examined in this update: 0.

Historical scorecards declare schema 5.4. This enrichment uses HSEF v5.3 causal distinctions without retrospectively relabelling or rescoring those files.

Targeted paper-check scope: Main P12 and statistical Methods P62: cell-type-specific chemogenetic silencing with control virus/ligand timing, and receptor-knockout structural comparisons. This does not isolate structural plasticity as the human mediator.

Editorial correction/limit: Primary source 37 reports a nonsignificant overall SV2A result. Positive setting-related comparisons must not replace that overall finding. The 2025 mouse study carries a correction notice.